Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04007276 · ClinicalTrials.gov registry record · Phase 4
The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients
A Phase 4 study, sponsored by Tulane University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT04007276 is a Phase 4 study that has not yet begun recruiting, run by Tulane University. The registered enrollment target is 60 participants.
The verdict
NCT04007276, a Phase 4 study, has not yet begun recruiting, sponsored by Tulane University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.
Interventions
- DRUG brimonidine tartrate ophthalmic solution 0.025%
- OTHER sterile balanced saline solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-11-10 |
| Est. Completion | 2036-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04007276
The ClinicalTrials.gov registry entry for NCT04007276 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which brimonidine tartrate ophthalmic solution 0.025% is the first listed.
NCT04007276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04007276 about?
NCT04007276 is a clinical study titled "The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients". Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approve...
What is the current status of trial NCT04007276?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2026-11-10. Estimated completion is 2036-06-01.
What interventions are being tested in trial NCT04007276?
The interventions under investigation include: brimonidine tartrate ophthalmic solution 0.025% (DRUG), sterile balanced saline solution (OTHER).
Who is sponsoring clinical trial NCT04007276?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.